{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:45:13Z","timestamp":1782438313213,"version":"3.54.5"},"reference-count":44,"publisher":"Becaris Publishing Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Complications of primary biliary cholangitis (PBC) are proposed to confer substantial economic burden to patients and healthcare systems. This retrospective observational study evaluated the cost of PBC-related hepatic decompensation and liver transplantation using a large administrative claims database.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    Patients aged \u226518\u00a0years at the time of first claim with a diagnosis of PBC were identified using Optum\u2019s de-identified Clinformatics\n                    <jats:sup>\u00ae<\/jats:sup>\n                    Data Mart Database. Two cohorts were established based on the type of event (hepatic decompensation or liver transplantation) that patients experienced on or after the date of their first claim with the PBC diagnosis. Costs for the hepatic decompensation hospitalization and 30-day post-discharge period were examined at the event level. Hospitalizations occurring within the 30-day post-discharge period after a hepatic decompensation event were considered readmissions, and costs from the initial event were combined with those from the ensuing readmissions. In the liver transplantation cohort, costs for the pretransplant evaluation, hospitalization for transplantation, and post-transplant care and complications were assessed per patient.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 2118 and 163 patients met study inclusion criteria in the hepatic decompensation and liver transplantation cohorts, respectively. The overall mean cost per hepatic decompensation event (n\u00a0=\u00a03581) was $63,612.09. The mean cost per event with readmission within 30\u00a0days (n\u00a0=\u00a0991, 27.7%) was $116,424.25; for events without readmission, the mean cost was $43,404.81. The mean total cost of liver transplantation per patient was $328,336.60. The mean cost per patient was highest for the hospitalization for transplantation ($226,908.70).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This comprehensive cost analysis demonstrates the high-cost burden of PBC disease progression. Appropriate patient management may help to mitigate the economic burden of PBC-related hepatic decompensation and liver transplantation.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0110","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:50:25Z","timestamp":1771239025000},"source":"Crossref","is-referenced-by-count":1,"title":["Cost of hepatic decompensation and liver transplantation events in primary biliary cholangitis: a retrospective observational study"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-3189","authenticated-orcid":false,"given":"Robert G","family":"Gish","sequence":"first","affiliation":[{"name":"Robert G. Gish Consultants, LLC, San Diego, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-1170","authenticated-orcid":false,"given":"Joanna P","family":"MacEwan","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Liu","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-3878","authenticated-orcid":false,"given":"Dannielle","family":"Lebovitch","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Nair","sequence":"additional","affiliation":[{"name":"Intercept Pharmaceuticals, Inc., Morristown, NJ 07960, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Bessonova","sequence":"additional","affiliation":[{"name":"Intercept Pharmaceuticals, Inc., Morristown, NJ 07960, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Intercept Pharmaceuticals, Inc., Morristown, NJ 07960, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M","family":"Younossi","sequence":"additional","affiliation":[{"name":"Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, VA 22042, USA"},{"name":"Center for Outcomes Research in Liver Disease, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"6","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: epidemiology, prognosis, and treatment","volume":"7","author":"Trivella J","year":"2023","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol. Commun. 7(6), e0179 (2023).","journal-title":"Hepatol. Commun."},{"issue":"1","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Bernstein D, Shiffman ML Diagnosis and management of primary biliary cholangitis. Am. J. Gastroenterol. 114(1), 48\u201363 (2019).","journal-title":"Am. J. Gastroenterol."},{"issue":"8","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment","volume":"16","author":"Lu M","year":"2018","unstructured":"Lu M, Zhou Y, Haller IV Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin. Gastroenterol. Hepatol. 16(8), 1342\u20131350.e1 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"e0677","DOI":"10.1097\/HC9.0000000000000677","article-title":"A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers","volume":"9","author":"Levy C","year":"2025","unstructured":"Levy C, Buchanan-Peart KA, MacEwan JP A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers. Hepatol. Commun. 9(5), e0677 (2025).","journal-title":"Hepatol. Commun."},{"issue":"2","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.14309\/ajg.0000000000002070","article-title":"Application of the latest advances in evidence-based medicine in primary biliary cholangitis","volume":"118","author":"Kowdley KV","year":"2023","unstructured":"Kowdley KV, Bowlus CL, Levy C Application of the latest advances in evidence-based medicine in primary biliary cholangitis. Am. J. Gastroenterol. 118(2), 232\u2013242 (2023).","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J. Hepatol. 67(1), 145\u2013172 (2017).","journal-title":"J. Hepatol."},{"issue":"1","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor KD","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 69(1), 394\u2013419 (2019).","journal-title":"Hepatology"},{"issue":"6","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers WJ","year":"2014","unstructured":"Lammers WJ, van Buuren HR, Hirschfield GM Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 147(6), 1338\u20131349.e5 (2014).","journal-title":"Gastroenterology"},{"key":"e_1_3_9_11_2","volume-title":"Full Prescribing Information","author":"Ocaliva (obeticholic acid)","year":"2022","unstructured":"Ocaliva (obeticholic acid). Full Prescribing Information. Intercept Pharmaceuticals Inc, NJ, USA (2022)."},{"issue":"6","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls","volume":"163","author":"Murillo Perez CF","year":"2022","unstructured":"Murillo Perez CF, Fisher H, Hiu S Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls. Gastroenterology 163(6), 1630\u20131642.e3 (2022).","journal-title":"Gastroenterology"},{"key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.dld.2024.01.007","article-title":"Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts","volume":"56","author":"Terracciani F","year":"2024","unstructured":"Terracciani F, De Vincentis A, D'Amato D Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts. Dig. Liver Dis. 56, S3\u2013S5 (2024).","journal-title":"Dig. Liver Dis."},{"issue":"6","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/HEP.0000000000001174","article-title":"Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): a trial emulation study design","volume":"81","author":"Brookhart MA","year":"2025","unstructured":"Brookhart MA, Mayne TJ, Coombs C Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): a trial emulation study design. Hepatology 81(6), 1647\u20131659 (2025).","journal-title":"Hepatology"},{"issue":"2","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14309\/ajg.0000000000003029","article-title":"COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls","volume":"120","author":"Kowdley KV","year":"2025","unstructured":"Kowdley KV, Hirschfield GM, Coombs C COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls. Am. J. Gastroenterol. 120(2), 390\u2013400 (2025).","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_9_16_2","volume-title":"Intercept announces voluntary withdrawal of OCALIVA\u00ae for primary biliary cholangitis (PBC) from the US market; US clinical trials involving obeticholic acid placed on clinical hold. Press release","year":"2025","unstructured":"Intercept announces voluntary withdrawal of OCALIVA\u00ae for primary biliary cholangitis (PBC) from the US market; US clinical trials involving obeticholic acid placed on clinical hold. Press release. Intercept Pharmaceuticals (2025). Accessed 11 September 2025. https:\/\/www.interceptpharma.com\/about-us\/news\/?id=3148535"},{"key":"e_1_3_9_17_2","volume-title":"Full Prescribing Information","author":"Iqirvo (elafibranor)","year":"2024","unstructured":"Iqirvo (elafibranor). Full Prescribing Information. Ipsen Biopharmaceuticals, Inc, MA, USA (2024)."},{"key":"e_1_3_9_18_2","volume-title":"Full Prescribing Information","author":"Livdelzi (seladelpar)","year":"2024","unstructured":"Livdelzi (seladelpar). Full Prescribing Information. Gilead Sciences, Inc, CA, USA (2024)."},{"issue":"1","key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.mayocpiqo.2023.08.005","article-title":"The burden of chronic disease","volume":"8","author":"Hacker K","year":"2024","unstructured":"Hacker K. The burden of chronic disease. Mayo Clin. Proc. Innov. Qual. Outcomes. 8(1), 112\u2013119 (2024).","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes."},{"issue":"6","key":"e_1_3_9_20_2","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/j.amepre.2017.07.019","article-title":"Prevalence and medical costs of chronic diseases among adult Medicaid beneficiaries","volume":"53","author":"Chapel JM","year":"2017","unstructured":"Chapel JM, Ritchey MD, Zhang D, Wang G. Prevalence and medical costs of chronic diseases among adult Medicaid beneficiaries. Am. J. Prev. Med. 53(6S2), S143\u2013S154 (2017).","journal-title":"Am. J. Prev. Med."},{"issue":"9","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/MCG.0000000000001120","article-title":"Factors associated with potential progressive course of primary biliary cholangitis: data from real-world US database","volume":"53","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Stepanova M, Golabi P Factors associated with potential progressive course of primary biliary cholangitis: data from real-world US database. J. Clin. Gastroenterol. 53(9), 693\u2013698 (2019).","journal-title":"J. Clin. Gastroenterol."},{"issue":"3","key":"e_1_3_9_22_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/hep4.1314","article-title":"Burden of primary biliary cholangitis among inpatient population in the United States","volume":"3","author":"Shahab O","year":"2019","unstructured":"Shahab O, Sayiner M, Paik J, Felix S, Golabi P, Younossi ZM. Burden of primary biliary cholangitis among inpatient population in the United States. Hepatol. Commun. 3(3), 356\u2013364 (2019).","journal-title":"Hepatol. Commun."},{"issue":"1","key":"e_1_3_9_23_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.30174","article-title":"Primary biliary cholangitis in Medicare population: the impact on mortality and resource use","volume":"69","author":"Sayiner M","year":"2019","unstructured":"Sayiner M, Golabi P, Stepanova M Primary biliary cholangitis in Medicare population: the impact on mortality and resource use. Hepatology 69(1), 237\u2013244 (2019).","journal-title":"Hepatology"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0174"},{"issue":"10","key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/MCG.0000000000001409","article-title":"Real-world comorbidity burden, health care utilization, and costs of nonalcoholic steatohepatitis patients with advanced liver diseases","volume":"55","author":"Wong RJ","year":"2021","unstructured":"Wong RJ, Kachru N, Martinez DJ, Moynihan M, Ozbay AB, Gordon SC. Real-world comorbidity burden, health care utilization, and costs of nonalcoholic steatohepatitis patients with advanced liver diseases. J. Clin. Gastroenterol. 55(10), 891\u2013902 (2021).","journal-title":"J. Clin. Gastroenterol."},{"key":"e_1_3_9_26_2","volume-title":"Optum claims data","unstructured":"Optum claims data. Optum, Accessed 1 October 2024. https:\/\/www.optum.com\/en\/business\/life-sciences\/real-world-data\/claims-data.html"},{"key":"e_1_3_9_27_2","volume-title":"Health data sources: claims data","unstructured":"Health data sources: claims data. National Library of Medicine, Accessed 26 August 2025. https:\/\/www.nlm.nih.gov\/oet\/ed\/stats\/03-300.html"},{"issue":"3","key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1155\/2010\/237860","article-title":"Validation of coding algorithms for the identification of patients with primary biliary cirrhosis using administrative data","volume":"24","author":"Myers RP","year":"2010","unstructured":"Myers RP, Shaheen AA, Fong A Validation of coding algorithms for the identification of patients with primary biliary cirrhosis using administrative data. Can. J. Gastroenterol. 24(3), 175\u2013182 (2010).","journal-title":"Can. J. Gastroenterol."},{"issue":"10","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"e70013","DOI":"10.1002\/pds.70013","article-title":"Identifying patients with primary biliary cholangitis and cirrhosis using administrative data in a national cohort","volume":"33","author":"John BV","year":"2024","unstructured":"John BV, Bastaich D, Dahman B, Veterans Analysis of Liver Disease Group of Investigators. Identifying patients with primary biliary cholangitis and cirrhosis using administrative data in a national cohort. Pharmacoepidemiol. Drug Saf. 33(10), e70013 (2024).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"e_1_3_9_30_2","first-page":"188","article-title":"Charlson Comorbidity Index: ICD-9 update and ICD-10 translation","volume":"12","author":"Glasheen WP","year":"2019","unstructured":"Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am. Health Drug Benefits 12(4), 188\u2013197 (2019).","journal-title":"Am. Health Drug Benefits"},{"issue":"8","key":"e_1_3_9_31_2","doi-asserted-by":"crossref","first-page":"e0201120","DOI":"10.1371\/journal.pone.0201120","article-title":"Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: a validation study","volume":"13","author":"Lapointe-Shaw L","year":"2018","unstructured":"Lapointe-Shaw L, Georgie F, Carlone D Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: a validation study. PLoS One 13(8), e0201120 (2018).","journal-title":"PLoS One"},{"issue":"7","key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/pds.2148","article-title":"Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study","volume":"20","author":"Lo Re V","year":"2011","unstructured":"Lo Re V III, Lim JK, Goetz MB Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol. Drug Saf. 20(7), 689\u2013699 (2011).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"e_1_3_9_33_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins SW","year":"2021","unstructured":"Biggins SW, Angeli P, Garcia-Tsao G Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 74(2), 1014\u20131048 (2021).","journal-title":"Hepatology"},{"issue":"3","key":"e_1_3_9_34_2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.26972","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"59","author":"Martin P","year":"2014","unstructured":"Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 59(3), 1144\u20131165 (2014).","journal-title":"Hepatology"},{"issue":"9","key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.dld.2020.07.029","article-title":"Cost of illness of primary biliary cholangitis - a population-based study","volume":"53","author":"Gerussi A","year":"2021","unstructured":"Gerussi A, Restelli U, Croce D, Bonfanti M, Invernizzi P, Carbone M. Cost of illness of primary biliary cholangitis - a population-based study. Dig. Liver Dis. 53(9), 1167\u20131170 (2021).","journal-title":"Dig. Liver Dis."},{"issue":"8","key":"e_1_3_9_36_2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.cgh.2017.10.018","article-title":"Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems","volume":"16","author":"Lu M","year":"2018","unstructured":"Lu M, Li J, Haller IV Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems. Clin. Gastroenterol. Hepatol. 16(8), 1333\u20131341.e6 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"e_1_3_9_37_2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/hep.31776","article-title":"Male sex is associated with higher rates of liver-related mortality in primary biliary cholangitis and cirrhosis","volume":"74","author":"John BV","year":"2021","unstructured":"John BV, Aitcheson G, Schwartz KB Male sex is associated with higher rates of liver-related mortality in primary biliary cholangitis and cirrhosis. Hepatology 74(2), 879\u2013891 (2021).","journal-title":"Hepatology"},{"issue":"11","key":"e_1_3_9_38_2","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/apt.70120","article-title":"Longitudinal relationship between elevated liver biochemical tests and negative clinical outcomes in primary biliary cholangitis: a population-based study","volume":"61","author":"Kowdley KV","year":"2025","unstructured":"Kowdley KV, Victor DWI, MacEwan JP Longitudinal relationship between elevated liver biochemical tests and negative clinical outcomes in primary biliary cholangitis: a population-based study. Aliment. Pharmacol. Ther. 61(11), 1775\u20131784 (2025).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"e_1_3_9_39_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.14309\/ajg.0000000000000512","article-title":"Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis","volume":"115","author":"Gordon SC","year":"2020","unstructured":"Gordon SC, Wu KH, Lindor K Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis. Am. J. Gastroenterol. 115(2), 262\u2013270 (2020).","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"e_1_3_9_40_2","doi-asserted-by":"crossref","first-page":"100931","DOI":"10.1016\/j.jhepr.2023.100931","article-title":"Critical shortfalls in the management of PBC: results of a UK-wide, population-based evaluation of care delivery","volume":"6","author":"Abbas N","year":"2024","unstructured":"Abbas N, Smith R, Flack S Critical shortfalls in the management of PBC: results of a UK-wide, population-based evaluation of care delivery. JHEP Rep. 6(1), 100931 (2024).","journal-title":"JHEP Rep."},{"issue":"7","key":"e_1_3_9_41_2","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/apt.12435","article-title":"Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid","volume":"38","author":"Boberg KM","year":"2013","unstructured":"Boberg KM, Wisloff T, Kjollesdal KS, Stovring H, Kristiansen IS. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment. Pharmacol. Ther. 38(7), 794\u2013803 (2013).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"e_1_3_9_42_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms MH","year":"2019","unstructured":"Harms MH, van Buuren HR, Corpechot C Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J. Hepatol. 71(2), 357\u2013365 (2019).","journal-title":"J. Hepatol."},{"issue":"6","key":"e_1_3_9_43_2","first-page":"371","article-title":"Secondary analysis of existing data: opportunities and implementation","volume":"26","author":"Cheng HG","year":"2014","unstructured":"Cheng HG, Phillips MR. Secondary analysis of existing data: opportunities and implementation. Shanghai Arch. Psychiatry 26(6), 371\u2013375 (2014).","journal-title":"Shanghai Arch. Psychiatry"},{"key":"e_1_3_9_44_2","doi-asserted-by":"crossref","first-page":"e000857","DOI":"10.1136\/bmjgast-2021-000857","article-title":"Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis","volume":"9","author":"Gungabissoon U","year":"2022","unstructured":"Gungabissoon U, Gibbons DC, Requena G, Ribeiro de Souza A, Smith H. Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis. BMJ Open Gastroenterol. 9, e000857 (2022).","journal-title":"BMJ Open Gastroenterol."},{"issue":"5","key":"e_1_3_9_45_2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cgh.2016.07.020","article-title":"Direct and indirect economic burden of chronic liver disease in the United States","volume":"15","author":"Stepanova M","year":"2017","unstructured":"Stepanova M, De Avila L, Afendy M Direct and indirect economic burden of chronic liver disease in the United States. Clin. Gastroenterol. Hepatol. 15(5), 759\u2013766.e5 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"e_1_3_9_46_2","doi-asserted-by":"crossref","first-page":"46958019838118","DOI":"10.1177\/0046958019838118","article-title":"Medicaid patients have greater difficulty scheduling health care appointments compared with private insurance patients: a meta-analysis","volume":"56","author":"Hsiang WR","year":"2019","unstructured":"Hsiang WR, Lukasiewicz A, Gentry M Medicaid patients have greater difficulty scheduling health care appointments compared with private insurance patients: a meta-analysis. Inquiry 56, 46958019838118 (2019).","journal-title":"Inquiry"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:53:34Z","timestamp":1772801614000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.57264\/cer-2025-0110"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0110","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"e250110"}}